OPER Technology Limited

09/03/2022

We strive to improve the quality of life for patients.

22/07/2020

Today is the World Brain Day 2020, The Hong Kong Movement Disorder Society Company Limited has invited our co-founder, Prof. Ken Yung, to share his expertise on nanotechnology invention as a potential treatment for Parkinson's Disease.
Let's move together to end Parkinson's Disease!

21/05/2020

【IF向財政司司長遞交意見書】

今年2月及4月，Innovate for Future（簡稱IF）先後向財政司司長遞交兩份意見書，指出在新型冠狀病毒疫情下，香港創科界面臨融資困難、資金枯竭的情況，並指出可行的短期對策。這些意見都是IF成員作為業內人士憑籍實際經驗提出。直至昨日（2020年5月20日），IF共18位核心成員在今天與財政司司長陳茂波先生和創新及科技局副局長鍾偉強博士在政府總部會面，闡述香港創科界的處境，並提出短期和中長期的對應方略。

#香港創科 #創科 #香港創新科技 #科技創新 #創意科技 #香港創業 #香港科學 #香港科技 #香港政策 #創新及科技局 #創新科技署

29/01/2020

Researchers have completed the first MRI-based mapping of the squid brain in 50 years, developing an atlas of neural connections, including those which are involved in camouflage.

04/12/2019

Congratulations to our CEO, Dr. Cathy N.P. Lui, on being awarded with the Young Achiever of the Year award and the Greater Bay Area Outstanding Young Women Entrepreneur Award recently in recognition of her great achievements in the field of biotechnology and the development of the Greater Bay Area.

#浸大 #生物系 校友、 #薈新科技有限公司 聯合創辦人兼行政總裁 #雷雅萍博士 近日分別榮獲由 #香港美國商會 頒發的「最具影響力女性——傑出女青」獎及由 #香港中小型企業聯合會 及新城財經台聯合頒發的「大灣區傑出青年女企業家獎」，以表揚她在 #生物科技 領域的領導潛能及對大灣區發展的貢獻。她的生物科技初創公司主要研發 #個人化幹細胞療法 和 #納米醫學 等創新技術。http://bit.ly/33N697N

Dr Cathy Lui, an alumna of ’s Department of , and CEO and co-founder of Technology Limited, was recently presented with the “Young Achiever of the Year” award by the American Chamber of Commerce and the “Greater Bay Area Outstanding Young Women Entrepreneur Award” by the Hong Kong Small and Medium Enterprises Association and FM 104 Metro Finance respectively, in recognition of her achievements in the field of biotechnology and also the development of the Greater Bay Area. Her biotech startup mainly focuses on the development of innovative technologies such as personalised stem cell therapies and . http://bit.ly/2sJTplp

影片：雷雅萍 – 從決心到關心 https://bit.ly/2B8hXVx
BUers Say movie on the achievements of Dr Cathy Lui https://bit.ly/2B8hXVx

HKBU Biology OPER Technology Limited American Chamber of Commerce

=========================
【 #香港浸會大學】Hong Kong Baptist University
https://hkbu.edu.hk
Instagram/Twitter ＠hkbaptistu
LinkedIn https://linkedin.com/school/hong-kong-baptist-university
https://talent100.hkbu.edu.hk/

14/11/2019

Congratulations to our CEO and Co-founder, Dr. Cathy Lui, being honoured as Young Achiever of the Year 2019 by the American Chamber of Commerce in Hong Kong (AmCham). This award recognises exceptional achievements and commitment for female leadership in business.

14/11/2019

14/11/2019 - 8:23 AmCham Women of Influence Awards

https://www.rthk.hk/radio/radio3/programme/money_talk/episode/606852/contentindex/2

Cathy Lui (L), the Young Achiever of the Year of AmCham HK’s Women of Influence Awards and the CEO of OPER Technology Limited, comments on the challenges of being a female entrepreneur in an environment where men dominate the business sector and women are expected to to work harder to show their capabilities.

22/05/2019

【顛覆固有認知】【研究：大腦能製造新神經元】

(i-Cable news; Published: Mar 26, 2019)

https://www.facebook.com/watch/?v=2347240968933674

11/03/2019

https://www.facebook.com/ScienceNaturePage/videos/1318838034915118/

04/03/2019

https://www.facebook.com/SeekerMedia/videos/10155932883008387/

25/02/2019

Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in Texas
(Technology networks; Published: Apr 12, 2018)

Lonza is opening the world’s largest dedicated cell-and-gene-therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies – the next era in medicine – and with the mission of enabling them to deliver these types of treatments to patients around the world more quickly and efficiently.

During a grand opening ceremony in Pearland, TX (USA), Lonza executives and industry leaders will unveil the 300,000-square-foot (27,870 square-meter) facility and its offerings – highlighting its state-of-the-art, fully integrated, everything-under-one-roof access to some of the world's most innovative cell-and-gene-therapy manufacturing technologies.

"Lonza Houston will serve as a center of excellence for cell-and-gene-therapy process development from concept through pre-clinical, clinical and commercialization, all the way to the patient," says Andreas Weiler, Business Unit head for Emerging Technologies at Lonza Pharma & Biotech. "This facility has the potential to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases, under one roof. It will set a new standard in biopharmaceutical manufacturing and stand as one of four centers of excellence in cell and gene therapy in the only global network spanning three continents."

He adds: "Outstanding teams of top experts from around the world are gathered here and are empowered to elaborate on innovative concepts, develop and optimize complex processes, and seamlessly deliver cell and gene therapies that adhere to the industry’s current good manufacturing practices (cGMP) standards."

The Lonza Houston Center of Excellence is already operational and manufacturing for several customers. This facility is recruiting employees and will have more than 200 full-time staff including scientists, engineers, MBAs and biotechnology professionals by the end of 2018 and continue to recruit high-value positions as market demand increases.

“Lonza is committed to the evolution and cultivation of a diverse medical and life-science community in the Greater Houston area for many years to come," says Marc Funk, Lonza Pharma & Biotech Chief Operating Officer. “The site is well positioned to meet the demands of the growing cell-and-gene-therapy field. Combining this leading-edge facility with our unmatched experience and expertise in cell and gene therapy will allow us to provide a key advantage to biopharmaceutical companies and academic researchers and ultimately to the patients they serve.”

First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.